2021.11.01
I-Mab today announced the appointment of John Long as the Company’s Chief Financial Officer and Jielun Zhu as the Company’s Chief Strategy Officer, both effectively immediately.
2021.10.26
I-Mab today announced that the Company has entered into a strategic partnership with Sinopharm to strengthen its commercial capabilities and accelerate its commercialization transformation.
2021.10.22
I-Mab today announced that it will establish a new site focusing on Translational Medicine and Formulation Research in San Diego.
2021.10.18
I-Mab today announced that the CDE of the China NMPA has approved the IND submission for the initiation of phase 2 clinical trial of efineptakin alfa in combination with PD-1 antibody in patients with advanced solid tumors.
2021.10.13
I-Mab today announced that it has completed the patient enrollment of the phase 3 clinical trial of human CD38 antibody felzartamab in combination with lenalidomide as a second-line therapy in patients with multiple myeloma.
2021.10.05
I-Mab and ABL Bio jointly announced that data from the preclinical studies of TJ-CD4B/ABL111 and TJ-L14B/ABL503, will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place November 12 – 14, 2021.
2021.10.01
I-Mab today announced its participation in the following conferences in October.
2021.09.30
I-Mab today announced multiple clinical advancements of its anti-CD47 monoclonal antibody lemzoparlimab.
2021.09.28
I-Mab today announced that the Center for Drug Evaluation of China National Medical Products Administration has accepted the Company’s IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors in China.
2021.09.13
I-Mab will be added to the following FTSE ESG (Environmental, Social and Governance) Index Series, in addition to the FTSE Global Equity Index Series (“GEIS”).